Novabay Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
CEO Michael Kazley exercised pre-funded warrants for 11.3 million shares of Stablecoin Development Corp, resulting in a net increase in beneficial ownership.
Framework Ventures IV L.P. exercised pre-funded warrants to acquire 11,307,300 shares of Stablecoin Development Corp common stock.
R01 Fund LP and CEO Michael Kazley increased their stake in Stablecoin Development Corp through the exercise of pre-funded warrants.
Framework Ventures IV L.P. acquired 50,109,253 pre-funded warrants in Stablecoin Development Corp for $0.85 per warrant.
R01 Fund LP and affiliated entities have acquired 53,679,974 pre-funded warrants in Stablecoin Development Corp at $0.85 per warrant.
CEO Michael Kazley, through R01 Entities, acquired 53,679,974 pre-funded warrants of Stablecoin Development Corp at $0.85 per warrant.
Stablecoin Development Corp CEO Michael Kazley filed an amended Form 4 to reflect a 1-for-5 reverse stock split and anti-dilution adjustments to warrant holdings.
Framework Ventures IV L.P. updated its holdings in Stablecoin Development Corp following a 1-for-5 reverse stock split and significant anti-dilution adjustments.
Stablecoin Development Corp's major shareholders amended their ownership filings to reflect a 1-for-5 reverse stock split and anti-dilution warrant adjustments.
Stablecoin Development Corp director Paul Freiman was granted 140,000 restricted stock units as part of his compensation package.
Stablecoin Development Corp. reports that Director Yenyou Zheng was granted 140,000 Restricted Stock Units (RSUs) vesting over three years.
Stablecoin Development Corp. reports that Chief Financial Officer Tommy Law was granted 300,000 restricted stock units.
Michael John Kazley, CEO and Director of Stablecoin Development Corp (SDEV), was granted a substantial number of time-based and performance-based restricted stock units on March 31, 2026.
SEC Form 4 filing reveals Swan Sit, a Director at Stablecoin Development Corp (SDEV), was granted 140,000 restricted stock units.
David E. Lazar, a Director and 10% owner of NovaBay Pharmaceuticals, Inc., reported the conversion of preferred stock and a significant divestment of his holdings, marking an exit filing.
Framework Ventures entities significantly increased their beneficial ownership in NovaBay Pharmaceuticals through preferred stock conversions and pre-funded warrant acquisitions.
R01 Fund LP, a significant insider, has substantially increased its beneficial ownership in NovaBay Pharmaceuticals through preferred stock conversions and warrant issuance.
NovaBay Pharmaceuticals CEO Michael Kazley significantly increased his indirect beneficial ownership through the conversion of preferred stock and the purchase of pre-funded warrants.
Framework Ventures IV L.P. amended its Form 4 filing for NovaBay Pharmaceuticals, Inc. to include Michael Ernest Anderson as a reporting person, detailing significant preferred stock holdings convertible into common shares.
NovaBay Pharmaceuticals CEO Michael Kazley indirectly acquired convertible preferred stock through R01 Entities, potentially increasing common stock holdings.
Framework Ventures IV L.P. acquired significant convertible preferred stock in NovaBay Pharmaceuticals, Inc., increasing its beneficial ownership.
R01 Fund LP, a 10% owner and affiliate of NovaBay Pharmaceuticals, Inc. CEO Michael Kazley, acquired convertible preferred stock that will convert into 56.8 million common shares.
David E. Lazar, a Director and 10% owner of NovaBay Pharmaceuticals, Inc., sold a substantial portion of his Series D Preferred Stock and rights to Series E Preferred Stock to institutional investors.
Poplar Point Capital Partners LP, along with related entities and Jad Fakhry, reports acquiring additional shares of NovaBay Pharmaceuticals, increasing their holdings to over 1 million shares.
Poplar Point Capital Partners LP, along with related entities and Jad Fakhry, reports acquiring additional shares of NovaBay Pharmaceuticals, increasing their holdings to 991,569 shares.
Poplar Point Capital Partners LP, along with related entities and Jad Fakhry, reports acquiring additional shares of NovaBay Pharmaceuticals common stock between March 18 and March 25, 2025, increasing their holdings to 868,204 shares.
Poplar Point Capital Partners LP, along with related entities and Jad Fakhry, reports acquiring additional shares of NovaBay Pharmaceuticals common stock, increasing their holdings to over 800,000 shares.
Poplar Point Capital Partners and related entities continue to increase their holdings in NovaBay Pharmaceuticals through a series of open market purchases.
Poplar Point Capital Partners LP and related entities have increased their holdings in NovaBay Pharmaceuticals through a series of open market purchases.
Poplar Point Capital Partners LP and related entities report increased holdings in NovaBay Pharmaceuticals through recent stock purchases.